[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-403459-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-403459-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prep-prescribing-pre-exposure-prophylaxis-prep-pocket-guide","PrEP Prescribing - Pre-Exposure Prophylaxis (PrEP) Pocket Guide","","Pre-Exposure Prophylaxis (PrEP) is recommended for HIV prevention for adults and adolescents with ongoing risk through sex or injection drug use. PrEP should be discussed with all sexually active individuals and can be prescribed even when risk is denied, unless contraindicated. The guide specifies indications, contraindications, what to prescribe (daily oral, on-demand/2-1-1, and injection options), possible side effects, key cautions, and required lab screening and follow-up visit schedules to ensure HIV-negative status and adherence.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prep-prescribing-pre-exposure-prophylaxis-prep-pocket-guide/403459/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prep-prescribing-pre-exposure-prophylaxis-prep-pocket-guide/403459.png","ImageObject",300,407,{"name":42,"@type":43},"Maya Linwood","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-27",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Who should discuss and receive PrEP according to the guide?","Question",{"text":63,"@type":64},"Discuss PrEP with all sexually active adults and adolescents. Prescribe if requested, even if a person denies HIV risk factors, unless contraindicated.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What contraindications and timing guidance are provided for starting PrEP?",{"text":68,"@type":64},"Contraindications include known HIV infection and low weight, as well as reduced kidney function thresholds for TDF/FTC or TAF/FTC. If possible HIV exposure occurred within the past 72 hours, offer nPEP first and then consider PrEP.",{"name":70,"@type":61,"acceptedAnswer":71},"What monitoring labs and follow-up visit schedule does the guide recommend?",{"text":72,"@type":64},"Baseline testing includes an HIV test within 1 week before starting PrEP (ideally HIV Ag/Ab), with HIV RNA if infection is possible in the prior 2–4 weeks, plus STI and hepatitis testing as listed. After start, oral PrEP follow-up includes at least every 3 months HIV testing and STI screening, with additional kidney and lipid monitoring at defined intervals; injection PrEP includes HIV RNA at 1 month and HIV testing every 2 months.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},403459,1790642480,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":97,"preview_page_count":4},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","PRESCRIBING  \nPrEP  \nPre-Exposure Prophylaxis (PrEP) is recommended as an HIV prevention option for anyone with risks of acquiring HIV infection through sex or drug use.  \nPrEP INDICATIONS  \nDiscuss PrEP with all sexually active adults and adolescents. Prescribe if requested, even if person denies HIV risk factors (unless contraindicated) .  \nPrEP is recommended for anyone with:  \n• Condomless vaginal or anal sex with a partner of unknown HIV status  \n• HIV-positive sex partner (especially if partner's HIV viral load is detectable or unknown)  \n• A recent bacterial sexually transmitted infection (STI)(gonorrhea/chlamydia/syphilis)  \n• Injection drug use with sharing of needles/equipment  \n• Any survival/transactional sex  \n• Desire to conceive with a partner who is HIV-positive  \nCONTRAINDICATIONS  \n• HIV infection  \n• Weight \u003C 77 lbs  \n• Estimated creatinine clearance (eCrCl) \u003C 60 mL/min for TDF/FTC or \u003C 30 mL/min for TAF/FTC  \n• Possible HIV exposure within the past 72 hours: instead offer nPEP, then consider PrEP. (PEPline: 888-448-4911)  \nWHAT TO PRESCRIBE  \nDaily Oral PrEP  \n• Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC, Truvada, or generic equivalent)  \n-300 mg/200 mg, 1 tab orally (PO) daily, \\#30, 2 refills for a total supply of not more than 90 days  \nOR  \n• Tenofovir alafenamide/emtricitabine (TAF/FTC, Descovy)  \n-25 mg/200 mg, 1 tab PO daily, \\#30, 2 refills fora total supply of not more than 90 days  \n-Not recommended as PrEP by those at risk from receptive vaginal sex  \nOn-Demand or 2-1-1 Oral PrEP: Alternative for men who have sex with men (MSM) who have sex infrequently TDF/FTC (Truvada or generic equivalent)  \n• 300 mg/200 mg, \\#30 with 0 refills (test for HIV before refill)  \n• 2-1-1 PrEP dosing:  \n- 2 tabs PO taken 2-24 hours prior to having sex, then  \n- 1 tab PO 24 hours after first 2 tabs taken, then  \n- 1 tab PO 48 hours after first 2 tabs taken  \n- Continue 1 tab PO daily until 48 hours after last sexual encounter  \nInjection PrEP  \n• Cabotegravir (CAB, Apretude) 600 mg IM (gluteal muscle)  \n(optional: CAB 30 mg PO daily x 30 days as oral lead-in before 1st injection)  \n-initial dose, 2nd dose 1 month after 1st dose, then every 2 months  \nPOSSIBLE SIDE EFFECTS  \nOral PrEP (TDF/FTC, TAF/FTC)  \n• Nausea, diarrhea, or headache; usually mild and resolveswithin 1 month  \n• Renal dysfunction; typically reversible if PrEP is stopped (risk greater with TDF)  \n• Slight (1%) loss of bone mineral density over 1 year; no increased risk of fractures (risk greater with TDF)  \n• TAF: possible weight gain Injection PrEP (CAB)  \n• Injection site reactions  \nCAUTIONS  \n• Symptoms of possible acute HIV (e.g., flu-like illness); defer PrEP and evaluate immediately for acute HIV, including HIV RNA testing  \n• Be aware of local policies related to minors and HIV prevention/treatment  \n• Drug interactions: See product Prescribing Information Oral PrEP (TDF/FTC, TAF/FTC)  \n• Hepatitis B (HBV) infection can flare after stopping PrEP medications; check for HBV infection before starting PrEP  \n• Chronic kidney disease (CKD) or significant risk of CKD  \n• Osteoporosis Injection PrEP (CAB)  \n• Not studied for persons age \u003C 18, not recommended  \n• Pregnancy/breastfeeding: discuss benefits/possible risks  \nLAB SCREENING AND VISITS  \nAssessment and counseling: At each follow up visit: assess for signs/symptoms of acute HIV; assess and support adherence and HIV risk and risk-reduction behaviors; assess and manage adverse effects; conduct contraception/conception counseling as appropriate.  \nBaseline labs  \n• All: HIV test within 1 week before starting PrEP (ideally HIV Ag/Ab)  \n• HIV RNA (if possibly infected within the past 2-4 weeks)  \n• STI testing: gonorrhea/chlamydia (throat, rectum, and genital/urine screening according to sites of exposure), syphilis, hepatitis C (HCV) Ab, consider hepatitis A IgG.  \n• Oral PrEP: creatinine (for estimated CrCl), hepatitis B (HBV) sAb/cAb/Ag. For TAF/FTC: cholesterol and triglycerides.  \n","cbCaiefldYepPwX4","https://ap.wps.com/l/cbCaiefldYepPwX4","pdf",102117,"English","# PrEP Prescribing\n## PrEP Indications and Contraindications\n## What to Prescribe (Oral and Injection Options)\n## Possible Side Effects and Cautions\n## Lab Screening and Follow-up Visits\n## Counseling Topics and Key Messages","[{\"question\":\"Who should discuss and receive PrEP according to the guide?\",\"answer\":\"Discuss PrEP with all sexually active adults and adolescents. Prescribe if requested, even if a person denies HIV risk factors, unless contraindicated.\"},{\"question\":\"What contraindications and timing guidance are provided for starting PrEP?\",\"answer\":\"Contraindications include known HIV infection and low weight, as well as reduced kidney function thresholds for TDF/FTC or TAF/FTC. If possible HIV exposure occurred within the past 72 hours, offer nPEP first and then consider PrEP.\"},{\"question\":\"What monitoring labs and follow-up visit schedule does the guide recommend?\",\"answer\":\"Baseline testing includes an HIV test within 1 week before starting PrEP (ideally HIV Ag/Ab), with HIV RNA if infection is possible in the prior 2–4 weeks, plus STI and hepatitis testing as listed. After start, oral PrEP follow-up includes at least every 3 months HIV testing and STI screening, with additional kidney and lipid monitoring at defined intervals; injection PrEP includes HIV RNA at 1 month and HIV testing every 2 months.\"}]","PrEP Prescribing - Pre-Exposure Prophylaxis (PrEP) Pocket Guide | PDF",1790540609]